A decreased level of serum soluble Klotho is an independent biomarker associated with arterial stiffness in patients with chronic kidney disease - PubMed (original) (raw)

doi: 10.1371/journal.pone.0056695. Epub 2013 Feb 19.

Hitoshi Sugiyama, Hiroshi Morinaga, Tatsuyuki Inoue, Keiichi Takiue, Ayu Ogawa, Toshio Yamanari, Yoko Kikumoto, Haruhito Adam Uchida, Shinji Kitamura, Yohei Maeshima, Kazufumi Nakamura, Hiroshi Ito, Hirofumi Makino

Affiliations

A decreased level of serum soluble Klotho is an independent biomarker associated with arterial stiffness in patients with chronic kidney disease

Masashi Kitagawa et al. PLoS One. 2013.

Abstract

Background: Klotho was originally identified in a mutant mouse strain unable to express the gene that consequently showed shortened life spans. In humans, low serum Klotho levels are related to the prevalence of cardiovascular diseases in community-dwelling adults. However, it is unclear whether the serum Klotho levels are associated with signs of vascular dysfunction such as arterial stiffness, a major determinant of prognosis, in human subjects with chronic kidney disease (CKD).

Methods: We determined the levels of serum soluble Klotho in 114 patients with CKD using ELISA and investigated the relationship between the level of Klotho and markers of CKD-mineral and bone disorder (CKD-MBD) and various types of vascular dysfunction, including flow-mediated dilatation, a marker of endothelial dysfunction, ankle-brachial pulse wave velocity (baPWV), a marker of arterial stiffness, intima-media thickness (IMT), a marker of atherosclerosis, and the aortic calcification index (ACI), a marker of vascular calcification.

Results: The serum Klotho level significantly correlated with the 1,25-dihydroxyvitamin D level and inversely correlated with the parathyroid hormone level and the fractional excretion of phosphate. There were significant decreases in serum Klotho in patients with arterial stiffness defined as baPWV≥1400 cm/sec, atherosclerosis defined as maximum IMT≥1.1 mm and vascular calcification scores of ACI>0%. The serum Klotho level was a significant determinant of arterial stiffness, but not endothelial dysfunction, atherosclerosis or vascular calcification, in the multivariate analysis in either metabolic model, the CKD model or the CKD-MBD model. The adjusted odds ratio of serum Klotho for the baPWV was 0.60 (p = 0.0075).

Conclusions: Decreases in the serum soluble Klotho levels are independently associated with signs of vascular dysfunction such as arterial stiffness in patients with CKD. Further research exploring whether therapeutic approaches to maintain or elevate the Klotho level could improve arterial stiffness in CKD patients is warranted.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1

Figure 1. Correlation between the serum Klotho levels (pg/mL) and various parameters.

The relationships between the serum Klotho levels and patient age (years) (A), estimated glomerular filtration rate (eGFR) (mL/min/1.73 m2) (B) and markers of chronic kidney disease-mineral and bone disorder (CKD-MBD), including 1,25-dihydroxyvitamin D (1,25D) (pg/mL) (C), log intact parathyroid hormone (PTH) (pg/mL) (D), fractional excretion of phosphate (FEPi) (%) (E) and fractional excretion of calcium (FECa) (%) (F) are shown. The serum Klotho levels were inversely correlated with age and positively correlated with eGFR (A, B). Regarding CKD-MBD markers, the serum Klotho levels were significantly correlated with 1,25D and negatively correlated with log intact PTH and FEPi; however, no significant correlation was observed with FECa (C–F). (A–F) N = 114.

Figure 2

Figure 2. Box and line plots showing the levels of serum Klotho (pg/mL) according to the stratified levels of vascular dysfunction.

They include flow-mediated dilatation (FMD) (%), a marker of endothelial dysfunction (A), ankle-brachial pulse wave velocity (baPWV) (cm/sec), a marker of arterial stiffness (B), maximum intima-media thickness (max IMT) (mm), a marker of atherosclerosis (C), and the aortic calcification index (ACI) (%), a marker of vascular calcification (D). The serum Klotho levels were significantly lower in patients with FMD<6.0%, PWV≥1400 cm/s, max IMT≥1.1 mm and ACI>0% compared to patients with FMD≥6.0%, PWV<1400 cm/s, max IMT<1.1 mm and ACI = 0%, respectively (**A–D**). (**A**) N = 70 and n = 40 in FMD<6.0% and FMD≥6.0%, respectively. (**B**) N = 60 and n = 45 in PWV<1400 cm/s and PWV≥1400 cm/s, respectively. (**C**) N = 82 and n = 29 in max IMT<1.1 mm and max IMT≥1.1 mm, respectively. (**D**) N = 28 and n = 75 in ACI = 0% and ACI>0%, respectively. The boxes denote the medians and 25th and 75th percentiles. The lines mark the 5th and 95th percentiles.

Figure 3

Figure 3. Multivariate odds ratio for ankle-brachial pulse wave velocity (baPWV) among patients with CKD displayed as the odds ratio (OR) (solid boxes) with 95% confidence intervals (CIs) (horizontal limit lines).

For continuous variables, the unit of change is given in parenthesis based on the multivariate model described in Table 2. MBP, mean blood pressure; eGFR, estimated glomerular filtration rate; PTH, parathyroid hormone; 1,25D, 1,25-dihydroxyvitamin D; FGF23, fibroblast growth factor 23.

Similar articles

Cited by

References

    1. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, et al. (2003) Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108: 2154–2169. - PubMed
    1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296–1305. - PubMed
    1. Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, et al. (2006) Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69: 1945–1953. - PubMed
    1. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl: S1–130. - PubMed
    1. Moe SM, Drueke T (2008) Improving global outcomes in mineral and bone disorders. Clin J Am Soc Nephrol 3 Suppl 3: S127–130. - PMC - PubMed

MeSH terms

Substances

Grants and funding

A portion of this study was supported by a Research Grant from the Kidney Foundation Japan (JKFB10-20 and JKFB12-44) and a 2011 Chronic Kidney Disease Award to M.K., a Research Grant from the Japan Vascular Disease Research Foundation to H.S. and a Grant-in-Aid for Progressive Renal Diseases Research, Research on Intractable Disease, from the Ministry of Health, Labor and Welfare of Japan. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

LinkOut - more resources